Compare · BSTC vs FLXN
BSTC vs FLXN
Side-by-side comparison of BioSpecifics Technologies Corp (BSTC) and Flexion Therapeutics, Inc. (FLXN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSTC and FLXN operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- FLXN carries a market cap of $458.9M.
- FLXN has more recent analyst coverage (7 ratings vs 0 for BSTC).
- Company
- BioSpecifics Technologies Corp
- Flexion Therapeutics, Inc.
- Price
- -
- $25.11-0.20%
- Market cap
- -
- $458.9M
- 1M return
- -
- -0.20%
- 1Y return
- -
- -1.57%
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- n/a
- 2014
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 7
Flexion Therapeutics, Inc.
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
Latest BSTC
- SEC Form SC 13G/A filed
- SEC Form SC 13G/A filed
- SEC Form 1 filed
- Endo Completes Acquisition of BioSpecifics
- Endo Announces Expiration Of Hart-Scott-Rodino Waiting Period For BioSpecifics Tender Offer
- WeissLaw LLP Reminds BSTC, DNKN, NAV, and PNM, Shareholders About Its Ongoing Investigations
- Lifshitz Law Firm, P.C. Announces Investigation of BioSpecifics Technologies Corp., Cleveland BioLabs, Inc., Concho Resources Inc., CONSOL Energy Inc., CONSOL Coal Resources LP, Endurance International Group Holdings, Inc., GCI Liberty, Inc., Liberty Broadband Corporation, and PNM Resources, Inc.
- WeissLaw LLP Reminds BSTC, PNM, and DNKN Shareholders About Its Ongoing Investigations
- Rigrodsky & Long, P.A. Reminds Investors Of Investigation of BioSpecifics Technologies Corp. Buyout
- BioSpecifics Reports Third Quarter 2020 Financial and Operating Results
Latest FLXN
- Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer
- SEC Form 15-12B filed by Flexion Therapeutics, Inc.
- SEC Form EFFECT filed by Flexion Therapeutics, Inc.
- SEC Form 4 filed by Newtyn Management, Llc
- SEC Form 3: New insider Newtyn Management, Llc claimed ownership of 5,900,000 shares
- SEC Form 4: Stejbach Mark returned $107,364 worth of shares to the company (12,631 units at $8.50), closing all direct ownership in the company to cover taxes
- SEC Form 4: Milinazzo Alan returned $233,325 worth of shares to the company (27,450 units at $8.50), closing all direct ownership in the company to satisfy withholding tax
- SEC Form 4: Merrifield C Ann returned $161,500 worth of shares to the company (19,000 units at $8.50), closing all direct ownership in the company to cover withholding tax
- SEC Form 4: Lukatch Heath returned $76,500 worth of shares to the company (9,000 units at $8.50), closing all direct ownership in the company to satisfy tax liability
- SEC Form 4: Kwo Elizabeth returned $38,250 worth of shares to the company (4,500 units at $8.50), closing all direct ownership in the company (tax liability)